Transcriptional Heterogeneity Reveals Novel Therapeutic Vulnerabilities in Pediatric Acute Lymphoblastic Leukemia

Needs Statement

Clinical and research faculty, graduate and medical students, clinical and postdoctoral fellows, and research nurses in pediatric hematology-oncology need to be regularly updated on the latest data from clinical trials in pediatric patients with hematological-oncological disorders, on the advances in the development of targeted therapies, on the developments in ethical/legal issues related to end of life care, and on the new practice standards for follow-up care for long-term survivors. The series aims to increase knowledge and skills of the learners in these topic areas in order to enhance the quality of care, increase patient safety, and improve patient outcomes.

Educational Objectives

At the conclusion of the sessions, the participants should be able to:

• Discuss new research data in pediatric hematologic and oncologic disorders and incorporate these data into clinical and research activities.
• Identify ethical and legal issues pertaining to clinical care and research activities pertaining to pediatric hematology and oncology.
• Evaluate drug development in pediatric cancers and blood disorders.
• Analyze and interpret the significance of long-term survivorship issues in pediatric cancer and hematologic disorders.
• Develop an understanding of how QI cycles can be applied to a specific and common clinical problem.
• Learn how to improve communication between clinical teams in different medical settings.

Target Audience

Accreditation/Credit Designation

Baylor College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Baylor College of Medicine designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Policy

Baylor College of Medicine (BCM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians. BCM is committed to sponsoring CE activities that are scientifically based, accurate, current, and objectively presented.

In accordance with the ACCME Standards for Commercial Support, BCM has implemented a mechanism requiring everyone in a position to control the content of an educational activity (i.e., directors, planning committee members, faculty) to disclose any relevant financial relationships with commercial interests (drug/device companies) and manage/resolve any conflicts of interest prior to the activity. Individuals must disclose to participants the existence or non-existence of financial relationships at the time of the activity or within 24 months prior.

In addition, BCM has requested activity faculty/presenters to disclose to participants any unlabeled use or investigational use of pharmaceutical/device products; to use scientific or generic names (not trade names) in referring to products; and, if necessary to use a trade name, to use the names of similar products or those within a class. Faculty/presenters have also been requested to adhere to the ACCME's validation of clinical content statements.

BCM does not view the existence of financial relationships with commercial interests as implying bias or decreasing the value of a presentation. It is up to participants to determine whether the relationships influence the activity faculty with regard to exposition or conclusions. If at any time during this activity you feel that there has been commercial/promotional bias, notify the Activity Director or Activity Coordinator. Please answer the questions about balance and objectivity in the activity evaluation candidly.

All of the relevant financial relationships listed for these individuals have been mitigated.